Muntau, A. C. Et Al. 2021. Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at <4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial. ORPHANET JOURNAL OF RARE DISEASES , vol.16, no.1 .

Muntau, A. C., Burlina, A., Eyskens, F., Freisinger, P., Leuzzi, V., SİVRİ, H. S., ... Gramer, G.(2021). Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at <4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial. ORPHANET JOURNAL OF RARE DISEASES , vol.16, no.1.

Muntau, Ania Et Al. "Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at <4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial," ORPHANET JOURNAL OF RARE DISEASES , vol.16, no.1, 2021

Muntau, Ania C. Et Al. "Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at <4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial." ORPHANET JOURNAL OF RARE DISEASES , vol.16, no.1, 2021

Muntau, A. C. Et Al. (2021) . "Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at <4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial." ORPHANET JOURNAL OF RARE DISEASES , vol.16, no.1.

@article{article, author={Ania C. Muntau Et Al. }, title={Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at <4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre, randomised phase IIIb trial}, journal={ORPHANET JOURNAL OF RARE DISEASES}, year=2021}